Anti-DRAK2 antibody,Abcam,AB8419
Apoptosis is mediated by death domain containing adapter molecules and a caspase family of proteases. Certain serine/threonine protein kinases, such as ASK-1 and RIP,are mediators of apoptosis. Two novel serine/threonine kinases that induce apoptosis were recently identified and designated DRAK1 and DRAK2 (for DAP kinase-related apoptosis-inducing protein kinases) (1). DRAKs contain anN-terminal kinase domain and a C-terminal regulation domain. Overexpression of DRAK2 induces apoptosis. DRAKs have high sequence homology to DAP and ZIP kinases, and they represent a novel family of serine/threonine kinases, which mediates apoptosis through their catalytic activities. DRAK2 is located in nucleus and the messenger RNA was ubiquitously expressed in human tissues.
Host
Rabbit
Reactivity
Human
Application
WB, ICC/IF
Platform ID
BAB973200899

Abcam
Contact
Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215
Email:
Product Specifications
Scientific Background
Specifications
NameAnti-DRAK2 antibody
Cat. No.AB8419
HostRabbit
IsotypeIgG
ReactivityHuman
ApplicationWB, ICC/IF
ClonalityPolyclonal
Concentration1 mg/mL Batch dependent concentration
ImmunogenSynthetic Peptide within Human STK17B aa 350 to C-terminus. The exact immunogen used to generate this antibody is proprietary information.
PurityIon exchange chromatography
Appearance/FormLiquid
ShippingBlue Ice
FormulationpH: 7.2 Preservative: 0.02% Sodium azide
Storage+4°C
Regulatory StatusResearch Use Only
Scientific Background
Target data Phosphorylates myosin light chains (By similarity). Acts as a positive regulator of apoptosis. See full target information STK17B
Category Paths
- Products>Primary Antibodies>Polyclonal Antibodies
Request a product
Please provide the required information below so that we can quickly source your products.
